351 related articles for article (PubMed ID: 35257288)
1. Pharmacoproteomics of Brain Barrier Transporters and Substrate Design for the Brain Targeted Drug Delivery.
Huttunen KM; Terasaki T; Urtti A; Montaser AB; Uchida Y
Pharm Res; 2022 Jul; 39(7):1363-1392. PubMed ID: 35257288
[TBL] [Abstract][Full Text] [Related]
2. Regional Differences in the Absolute Abundance of Transporters, Receptors and Tight Junction Molecules at the Blood-Arachnoid Barrier and Blood-Spinal Cord Barrier among Cervical, Thoracic and Lumbar Spines in Dogs.
Takeuchi H; Suzuki M; Goto R; Tezuka K; Fuchs H; Ishiguro N; Terasaki T; Braun C; Uchida Y
Pharm Res; 2022 Jul; 39(7):1393-1413. PubMed ID: 35488144
[TBL] [Abstract][Full Text] [Related]
3. Inner Blood-Retinal Barrier Dominantly Expresses Breast Cancer Resistance Protein: Comparative Quantitative Targeted Absolute Proteomics Study of CNS Barriers in Pig.
Zhang Z; Uchida Y; Hirano S; Ando D; Kubo Y; Auriola S; Akanuma SI; Hosoya KI; Urtti A; Terasaki T; Tachikawa M
Mol Pharm; 2017 Nov; 14(11):3729-3738. PubMed ID: 28954515
[TBL] [Abstract][Full Text] [Related]
4. Impact of transporters and enzymes from blood-cerebrospinal fluid barrier and brain parenchyma on CNS drug uptake.
Wang Q; Zuo Z
Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):961-972. PubMed ID: 30118608
[TBL] [Abstract][Full Text] [Related]
5. [Molecular Mechanism Underlying the Function and Disintegration of the Central Nerve System Barrier Unraveled by Proteo-typing of Membrane Proteins].
Terasaki T
Brain Nerve; 2021 Jan; 73(1):59-78. PubMed ID: 33361514
[TBL] [Abstract][Full Text] [Related]
6. [Multi-disciplinary research approaches on the brain barrier transport system, a dynamic interface].
Tachikawa M; Uchida Y; Terasaki T
Brain Nerve; 2013 Feb; 65(2):121-36. PubMed ID: 23399670
[TBL] [Abstract][Full Text] [Related]
7. Abundant Expression of OCT2, MATE1, OAT1, OAT3, PEPT2, BCRP, MDR1, and xCT Transporters in Blood-Arachnoid Barrier of Pig and Polarized Localizations at CSF- and Blood-Facing Plasma Membranes.
Uchida Y; Goto R; Takeuchi H; Łuczak M; Usui T; Tachikawa M; Terasaki T
Drug Metab Dispos; 2020 Feb; 48(2):135-145. PubMed ID: 31771948
[TBL] [Abstract][Full Text] [Related]
8. Quantitative targeted proteomics for understanding the blood-brain barrier: towards pharmacoproteomics.
Ohtsuki S; Hirayama M; Ito S; Uchida Y; Tachikawa M; Terasaki T
Expert Rev Proteomics; 2014 Jun; 11(3):303-13. PubMed ID: 24702234
[TBL] [Abstract][Full Text] [Related]
9. Drug Delivery Strategies to Overcome the Blood-Brain Barrier (BBB).
Helms HCC; Kristensen M; Saaby L; Fricker G; Brodin B
Handb Exp Pharmacol; 2022; 273():151-183. PubMed ID: 33367937
[TBL] [Abstract][Full Text] [Related]
10. Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?
Sanchez-Covarrubias L; Slosky LM; Thompson BJ; Davis TP; Ronaldson PT
Curr Pharm Des; 2014; 20(10):1422-49. PubMed ID: 23789948
[TBL] [Abstract][Full Text] [Related]
11. [Membrane Transporters and Their Regulatory Mechanisms at the Brain and Retinal Barriers to Establish Therapies for Refractory Central Nervous System Diseases].
Akanuma SI
Yakugaku Zasshi; 2020; 140(10):1235-1242. PubMed ID: 32999202
[TBL] [Abstract][Full Text] [Related]
12. Involvement of Claudin-11 in Disruption of Blood-Brain, -Spinal Cord, and -Arachnoid Barriers in Multiple Sclerosis.
Uchida Y; Sumiya T; Tachikawa M; Yamakawa T; Murata S; Yagi Y; Sato K; Stephan A; Ito K; Ohtsuki S; Couraud PO; Suzuki T; Terasaki T
Mol Neurobiol; 2019 Mar; 56(3):2039-2056. PubMed ID: 29984400
[TBL] [Abstract][Full Text] [Related]
13. Targeting Transporters for Drug Delivery to the Brain: Can We Do Better?
Puris E; Fricker G; Gynther M
Pharm Res; 2022 Jul; 39(7):1415-1455. PubMed ID: 35359241
[TBL] [Abstract][Full Text] [Related]
14. Organic Anion-Transporting Polypeptide 1a4 (Oatp1a4/Slco1a4) at the Blood-Arachnoid Barrier is the Major Pathway of Sulforhodamine-101 Clearance from Cerebrospinal Fluid of Rats.
Yaguchi Y; Tachikawa M; Zhang Z; Terasaki T
Mol Pharm; 2019 May; 16(5):2021-2027. PubMed ID: 30977661
[TBL] [Abstract][Full Text] [Related]
15. Drug transporters on arachnoid barrier cells contribute to the blood-cerebrospinal fluid barrier.
Yasuda K; Cline C; Vogel P; Onciu M; Fatima S; Sorrentino BP; Thirumaran RK; Ekins S; Urade Y; Fujimori K; Schuetz EG
Drug Metab Dispos; 2013 Apr; 41(4):923-31. PubMed ID: 23298861
[TBL] [Abstract][Full Text] [Related]
16. Quantitative Determination of Luminal and Abluminal Membrane Distributions of Transporters in Porcine Brain Capillaries by Plasma Membrane Fractionation and Quantitative Targeted Proteomics.
Kubo Y; Ohtsuki S; Uchida Y; Terasaki T
J Pharm Sci; 2015 Sep; 104(9):3060-8. PubMed ID: 25703048
[TBL] [Abstract][Full Text] [Related]
17. Circadian ABCG2 Expression Influences the Brain Uptake of Donepezil across the Blood-Cerebrospinal Fluid Barrier.
Furtado A; Duarte AC; Costa AR; Gonçalves I; Santos CRA; Gallardo E; Quintela T
Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732233
[TBL] [Abstract][Full Text] [Related]
18. Selective induction of P-glycoprotein at the CNS barriers during symptomatic stage of an ALS animal model.
Chan GN; Evans RA; Banks DB; Mesev EV; Miller DS; Cannon RE
Neurosci Lett; 2017 Feb; 639():103-113. PubMed ID: 28011392
[TBL] [Abstract][Full Text] [Related]
19. Organic Cation Transporter (OCT/OCTN) Expression at Brain Barrier Sites: Focus on CNS Drug Delivery.
Betterton RD; Davis TP; Ronaldson PT
Handb Exp Pharmacol; 2021; 266():301-328. PubMed ID: 33674914
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Absolute Protein Abundances of Transporters and Receptors among Blood-Brain Barriers at Different Cerebral Regions and the Blood-Spinal Cord Barrier in Humans and Rats.
Uchida Y; Yagi Y; Takao M; Tano M; Umetsu M; Hirano S; Usui T; Tachikawa M; Terasaki T
Mol Pharm; 2020 Jun; 17(6):2006-2020. PubMed ID: 32310660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
